Last reviewed · How we verify
Endostar routine intravenous infusion
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (in combination with chemotherapy).
At a glance
| Generic name | Endostar routine intravenous infusion |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF signaling pathway; endothelial cells |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Endostar is a truncated form of human endostatin, an endogenous angiogenesis inhibitor derived from collagen XVIII. It works by suppressing vascular endothelial growth factor (VEGF)-mediated endothelial cell proliferation and migration, thereby starving tumors of their blood supply. This anti-angiogenic mechanism reduces tumor growth and metastatic potential.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Other solid tumors (in combination with chemotherapy)
Common side effects
- Hypertension
- Proteinuria
- Thromboembolism
- Hemorrhage
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: